Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

British rock icons Oasis began their long-awaited reunion tour this month, and it's not hard to see parallels between the ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented investors. Increases in dividend per share (DPS) greatly allow companies to ...

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

PFE is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock is trading with a P/E ratio of 7.98, which compares to its industry's average of 15.63.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...